+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free

Generalized Anxiety Disorder (GAD) Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2023

Pre Book Price: $ 5216

Original Price: $ 5795

Generalized anxiety disorder  is characterized by excessive anxiety and worry about everyday life events with no apparent reason. The patient  cannot stop worrying about health, family, money, or work and eventually anxiety dominates the person thinking, that interfere with daily functioning of person. Symptoms of generalized anxiety disorder includes an unrealistic view of problems, muscle tension, headache, sweating, and tiredness. Additionally, rarely GAD occurs alone as it often accompanied by other anxiety disorder, substance abuse, and depression. Number of factors are responsible to develop GAD which includes genetics, brain chemistry, and environmental factors such as trauma and stressful event, family background, or life experiences. The disorder comes on progressively and can arise across the life cycle, though the risk is highest between childhood and middle age. GAD is diagnosed when a person worries excessively of everyday problems for more than six months and has three or more symptoms. According to Centers for Disease Control and Prevention (CDC), prevalence of anxiety disorder in Europe is over 15 % of total Europe population. In addition, CDC stated that prevalence of disorder is more in women than men. Generally, psychotherapy is preferable to GAD patient before medication which teaches a person different ways of reacting, and thinking in various life situations.    

Generalized anxiety disorder market is segmented into therapeutics, and geography. The  therapeutics market is segmented into antidepressant, buspirone, and benzodiazepines. Antidepressants further segmented into selective serotonin reuptake inhibitor (SSRI), and serotonin norepinephrine reuptake inhibitor(SNRI). Benzodiazepines includes alprazolam (Niravam, Xanax), chlordiazepoxide (Librium), diazepam (Valium) and lorazepam. However, benzodiazepines can be habit forming hence, generally used for short term basis and consider as a last choice of treatment. Antidepressant are first line therapy for GAD patient hence, hold the largest market share globally. Geographically, generalized anxiety disorder market segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa, and Rest of the World (RoW). North America dominates the global generalized anxiety market due to increasing incidence of anxiety disorders, and more awareness in people related to anxiety and it is expected to maintain the position during forecast period. However, Asia Pacific market is expected to grow at a faster rate due to changing lifestyle lead to increasing stress, and growing facilities to detect anxiety disorders. 

Some of the major driving factors to propel the generalized anxiety disorders market are increasing incidence rate due to more stressful life, Sedentary lifestyle, and presence of strong pipeline. According to National Institute of Mental Health, every year GAD affects minimum 6.8 million adults, or 3.1% of the U.S. population. In the National Comorbidity Survey carried out in 2005, 58% of patients diagnosed with major depression were found to have an anxiety disorder; among these patients, the rate of comorbidity with GAD was 17.2%. However, poor diagnosis rate as no single diagnosis test is available to detect generalized anxiety disorder, affectivity of psychotherapy, and side effects of medications such as habit forming nature, dry mouth, and nausea could restraint the market growth. Focusing on emerging countries such as BRICS countries would create an opportunity for a market players.      

Some of the key players of the global generalized anxiety disorder market are Eli Lilly and Company, GlaxoSmithKline Pharmaceuticals Limited, Pfizer, Inc., Abbott Laboratories, Baxter International, Bristol-Myers Squibb, Actavis Pharmaceutical Company, F. Hoffmann-La Roche, Recordati Rare Diseases, Noven Pharmaceuticals, Inc., Sumitomo Dainippon Pharma, and Shionogi and Company.    

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include

  • North America
  • Asia Pacific
  • Europe
  • Middle East and Africa
  • Latin America

This report provides comprehensive analysis of

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Reasons for Buying this Report

  • This report provides pin-point analysis for changing competitive dynamics
  • It provides a forward looking perspective on different factors driving or restraining market growth
  • It provides a six-year forecast assessed on the basis of how the market is predicted to grow
  • It helps in understanding the key product segments and their future
  • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
  • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
  • It provides distinctive graphics and exemplified SWOT analysis of major market segments

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

To receive discount, please click on the button below.

Please click on the button below to customize this report.

Back To Top